New immunotherapy targets tough pancreatic cancers in early trial
NCT ID NCT05726864
First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 1 time
Summary
This early-phase trial tests an experimental immunotherapy called ELI-002 7P in people with pancreatic or other solid tumors that have specific KRAS or NRAS gene mutations. The treatment aims to train the immune system to attack cancer cells. About 158 participants will receive the drug or standard monitoring. The study checks safety and whether the treatment helps keep cancer from coming back.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Banner MD Anderson Cancer Center
Gilbert, Arizona, 85234, United States
-
Cedars-Sinai Medical Center
Los Angeles, California, 90048, United States
-
City of Hope
Duarte, California, 91010, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Emory Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
Lehigh Valley Health Network
Allentown, Pennsylvania, 18003, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02210, United States
-
Mayo Clinic Comprehensive Cancer Center
Phoenix, Arizona, 85054, United States
-
Mayo Clinic Comprehensive Cancer Center
Jacksonville, Florida, 32224, United States
-
Mayo Clinic Comprehensive Cancer Center
Rochester, Minnesota, 55905, United States
-
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10022, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
New York Presbyterian Weill Cornell Medical Center
New York, New York, 10065, United States
-
Northwell Health
Lake Success, New York, 11042, United States
-
Ochsner Health
New Orleans, Louisiana, 70121, United States
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of California Los Angeles
Los Angeles, California, 90095, United States
-
University of California, Irvine
Orange, California, 92868, United States
-
University of Colorado Hospital-Anschutz Cancer Pavillion
Aurora, Colorado, 80045, United States
-
University of Florida Health Cancer Center
Gainesville, Florida, 32610, United States
-
University of Iowa
Iowa City, Iowa, 52242, United States
-
University of Miami
Coral Gables, Florida, 33124, United States
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
University of Texas Southwestern
Dallas, Texas, 75390, United States
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37212, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we predict who will survive a bowel surgery leak?
- Can a new Liposome-Wrapped drug shrink Hard-to-Treat solid tumors?
- Can High-Dose vitamin c boost Chemo's punch against pancreatic cancer?
- Can a Two-Drug attack shrink Hard-to-Treat colorectal tumors?
- Can a tracer that hunts unstable iron light up hidden tumors?
- Can a new infusion drug tame advanced solid tumors?